<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927199</url>
  </required_header>
  <id_info>
    <org_study_id>B2007:071</org_study_id>
    <nct_id>NCT00927199</nct_id>
  </id_info>
  <brief_title>Efficacy of High-oleic Canola and Flaxseed Oils for Hypercholesterolemia and Cardiovascular Disease Risk Factors</brief_title>
  <official_title>Efficacy of Consumption of High-oleic Canola and Flaxseed Oils in the Management of Hypercholesterolemia and Other Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canola Council of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flax Canada 2015 Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agri-Food Research and Development Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of high-oleic canola oil and a high-oleic
      canola/flaxseed oil blend as compared to a typical Western diet on plasma lipids, fatty acid
      profiles, and risk factors associated with cardiovascular disease in hypercholesterolemic
      patients. Furthermore, the metabolism of dietary oleic acid and alpha-linolenic acid
      contained in high-oleic canola oil and flaxseed oil will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Lipids</measure>
    <time_frame>Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Biomarkers: C-Reactive Protein, Interleukin-6, sE-Selectin, sVCAM-1, sICAM-1</measure>
    <time_frame>Study Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intima-Medial Thickness by Carotid Ultrasound</measure>
    <time_frame>Study Baseline (during Day 1-3) and Endpoint (during Day 24-26) of each experimental phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Energy Expenditure by Indirect Calorimetry</measure>
    <time_frame>Study Baseline (during Week 1) and Endpoint (during Week 4) of each experimental phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Composition by Dual Emission X-Ray Absorptiometry (DEXA)</measure>
    <time_frame>Baseline (Day1,2) and Endpoint (Day 28,29) of each experimental phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxidation and Conversion of U-13C-Alpha Linolenic Acid</measure>
    <time_frame>Day 27 (time 0-8 hrs), Day 28 (24 hrs), Day 29 (48 hrs) of each experimental phase</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Fatty Acid Concentrations</measure>
    <time_frame>Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness Index by Pulse Wave Analysis</measure>
    <time_frame>Baseline (Day 1,2) and Endpoint (Day 28,29) of each experimental phase</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>High-Oleic Canola Oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High-Oleic Canola/Flaxseed Oil Blend</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Western Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-Oleic Canola Oil</intervention_name>
    <description>Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))</description>
    <arm_group_label>High-Oleic Canola Oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High-Oleic Canola/Flaxseed Oil Blend</intervention_name>
    <description>Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))</description>
    <arm_group_label>High-Oleic Canola/Flaxseed Oil Blend</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Western Dietary Control</intervention_name>
    <description>Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))</description>
    <arm_group_label>Western Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting serum LDL-Cholesterol &gt;3.0 mmol/L

          -  Body mass index (BMI) between 22-36 kg/m2

        Exclusion Criteria:

          -  smoking

          -  use of lipid lowering therapy

          -  documented cardiovascular/atherosclerotic disease

          -  inflammatory disease

          -  diabetes

          -  uncontrolled hypertension

          -  kidney disease

          -  other systemic diseases

          -  cancer

          -  chronic alcohol consumption (&gt; 2 servings/day)

          -  excessive exercise expenditure (&gt; 4000 kcal/week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter JH Jones, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba - Richardson Centre for Functional Foods and Nutraceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 6C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.umanitoba.ca/research/rcffn/</url>
    <description>Richardson Centre for Functional Foods and Nutraceuticals - website home page</description>
  </link>
  <reference>
    <citation>Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011 Mar;46(3):209-28. doi: 10.1007/s11745-010-3524-y. Epub 2011 Feb 10. Review.</citation>
    <PMID>21308420</PMID>
  </reference>
  <results_reference>
    <citation>Gillingham LG, Harding SV, Rideout TC, Yurkova N, Cunnane SC, Eck PK, Jones PJ. Dietary oils and FADS1-FADS2 genetic variants modulate [13C]Î±-linolenic acid metabolism and plasma fatty acid composition. Am J Clin Nutr. 2013 Jan;97(1):195-207. doi: 10.3945/ajcn.112.043117. Epub 2012 Dec 5.</citation>
    <PMID>23221573</PMID>
  </results_reference>
  <results_reference>
    <citation>Gillingham LG, Robinson KS, Jones PJ. Effect of high-oleic canola and flaxseed oils on energy expenditure and body composition in hypercholesterolemic subjects. Metabolism. 2012 Nov;61(11):1598-605. doi: 10.1016/j.metabol.2012.04.016. Epub 2012 Jun 12.</citation>
    <PMID>22698766</PMID>
  </results_reference>
  <results_reference>
    <citation>Gillingham LG, Gustafson JA, Han SY, Jassal DS, Jones PJ. High-oleic rapeseed (canola) and flaxseed oils modulate serum lipids and inflammatory biomarkers in hypercholesterolaemic subjects. Br J Nutr. 2011 Feb;105(3):417-27. doi: 10.1017/S0007114510003697. Epub 2010 Sep 29.</citation>
    <PMID>20875216</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <name_title>Peter J.H. Jones, PhD; Principal Investigator</name_title>
    <organization>Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba</organization>
  </responsible_party>
  <keyword>High-Oleic Canola Oil</keyword>
  <keyword>Flaxseed Oil</keyword>
  <keyword>Monounsaturated Fatty Acids</keyword>
  <keyword>Polyunsaturated Fatty Acids</keyword>
  <keyword>Alpha Linolenic Acid</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Lipids</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

